Pediatric Non-alcoholic Fatty Liver Disease

Related Experiment Video

Updated: Mar 22, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

2.0K

Vikas Uppal1,2, Sana Mansoor1,2, Katryn N Furuya3,4

  • 1Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Alfred I duPont Hospital for Children, Wilmington, DE, USA.

Current Gastroenterology Reports
|April 18, 2016
PubMed

Insights

Childhood obesity is rising, leading to more pediatric non-alcoholic fatty liver disease (NAFLD). Research is exploring causes, diagnosis, and treatments, including lifestyle changes and new therapies.

Area of Science:

  • Pediatric gastroenterology and hepatology
  • Public health and epidemiology
  • Microbiome research

Background:

  • Childhood obesity affects over one-third of American children, increasing liver disease prevalence.
  • Non-alcoholic fatty liver disease (NAFLD) is now the most common chronic liver disease in children.
  • Emerging research investigates the complex factors contributing to pediatric NAFLD.

Purpose of the Study:

  • To review current understanding of pediatric NAFLD, including pathogenesis and genetic factors.
  • To highlight advancements in non-invasive diagnostic methods for hepatic steatosis and fibrosis.
  • To summarize treatment strategies, focusing on lifestyle interventions and ongoing clinical trials.

Main Methods:

  • Literature review of pathogenesis, genetics, and microbiome in pediatric NAFLD.
  • Analysis of new non-invasive diagnostic modalities for liver conditions.
  • Overview of current lifestyle and pharmacological treatment trials.

Main Results:

  • Significant increase in pediatric NAFLD cases linked to obesity epidemic.
  • Development of novel non-invasive techniques for diagnosing liver conditions in children.
  • Ongoing clinical trials exploring innovative treatments for pediatric NAFLD.

Conclusions:

  • Pediatric NAFLD is a growing public health concern requiring further research.
  • Non-invasive diagnostics are crucial for monitoring disease progression in children.
  • Lifestyle interventions combined with emerging therapies offer hope for managing pediatric NAFLD.

Keywords:
Childhood obesityCirrhosisHepatic fibrosisNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisPediatric

More Related Videos

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

676
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.8K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
317
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
669
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
254
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
441
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K